NASDAQ: LIMNLiminatus Pharma Inc Stock
$12.80-0.01 (-0.08%)
Updated Jun 18, 2025
LIMN Price
$12.80
Fair Value Price
N/A
Market Cap
$332.99M
52 Week Low
$4.40
52 Week High
$26.68
P/E
N/A
P/B
-16.93x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.31
Operating Cash Flow
N/A
Beta
-2.14
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LIMN Overview
Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LIMN's potential to beat the market
- LIMN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LIMN
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.92 | A | |
| $22.81 | A | |
| $40.74 | A |
Be the first to know about important LIMN news, forecast changes, insider trades & much more!
LIMN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LIMN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LIMN's short-term liabilities ($25.79M) exceed its short-term assets ($6.00M)
Short-term Liabilities Financials
LIMN's short-term assets ($6.00M) exceed its long-term liabilities ($0.00)
Long-term Liabilities Financials
LIMN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more LIMN due diligence checks available for Premium users.
Valuation
LIMN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-16.93x
Industry
4.5x
LIMN's financial health
Profit margin
Revenue
$0.0
Net Income
-$328.0k
Profit Margin
0%
Assets to liabilities
Assets
$6.1M
Liabilities
$25.8M
Debt to equity
-1.31
LIMN's short-term liabilities ($25.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LIMN's short-term assets ($6.00M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LIMN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LIMN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$159.0k
Investing
-$575.0k
Financing
$713.0k
LIMN vs Biotech Stocks
Liminatus Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.